March 16, 2000 |
The biotech group has taken a pounding, with the Amex sector index sliding 29% since it soared to a record early last week. But Wednesday, Wall Street analysts indicated the prognosis appears healthy for several stocks in the volatile sector, issuing several "strong buy" ratings, including: * PE Corp.-Celera Genomics Group (CRA; $146, down $8) at ING Barings, with a $300 target.
May 10, 2000 |
Nexell Therapeutics Inc.'s surging stock made another strong advance Tuesday after the Irvine company said Japan's largest maker of distilled spirits will sell Nexell's biotechnology products in Asia. The stock, which has more than quadrupled so far this year, moved up 28% during the session before settling back to $5.66, a gain of 64 cents, or 13%, in heavy Nasdaq trading.
April 11, 2000 |
The volatile shares of PE Corp.'s Celera Genomics (ticker symbol: CRA) tumbled 23% on Monday as a scientist running a rival project to decode human DNA questioned Celera's claim to a major step forward in the process. The Norwalk, Conn., company's stock, which had soared to $276 in late February, fell $30.38 to close at $100 on the NYSE. Other genome-research shares also tumbled, including Myriad Genetics (MYGN), down $12.50 to $55, and Millennium Pharmaceuticals (MLNM), down $23.75 to $149.50.
June 27, 2000 |
To his admirers and shareholders, J. Craig Venter is a corporate wizard of gene deciphering, a magician of the genetic code. As president and chief scientific officer of Celera Genomics, his vision has allowed the 2-year-old company to lay claim to what is arguably the more complete of the two versions of the human genome--the genetic instruction manual for the human body.
January 2, 2000 |
Who will make big news in the business world this year? Who will emerge from relative obscurity to become a major player? To start the new year, Times business reporters selected people from their beats who they believe will be among those to watch in 2000--in Southern California, across the country and around the world. Some are well known, having made big news in previous years. Others are not exactly household names but nevertheless are likely to make a major impact in their fields.
April 6, 2000 |
Beaten-down biotechnology shares surged Wednesday after President Clinton reassured the industry that its commercial gene discoveries could be patented. Among the biggest gainers were shares of companies specifically involved in research into the human genome--the recipe book of genes that form a person. PE Corp.-Celera soared $41.38 to $115, Human Genome Sciences surged $16 to $97, Millennium Pharmaceuticals leaped $21.36 to $143.36 and Sequenom rocketed $9.38 to $33.50.